Serina Therapeutics, Inc.
SER · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $130 | $0 | -$14 |
| % Growth | -100% | – | 100% | – |
| Cost of Goods Sold | $17 | $16 | $17 | $0 |
| Gross Profit | -$17 | $114 | -$17 | -$14 |
| % Margin | – | 87.7% | – | 100% |
| R&D Expenses | $3,634 | $3,152 | $2,951 | $2,365 |
| G&A Expenses | $0 | $2,543 | $0 | $3,170 |
| SG&A Expenses | $2,741 | $2,543 | $2,890 | $3,170 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$16 | $0 | $0 |
| Operating Expenses | $6,375 | $5,679 | $5,841 | $5,535 |
| Operating Income | -$6,392 | -$5,565 | -$5,858 | -$5,549 |
| % Margin | – | -4,280.8% | – | 39,635.7% |
| Other Income/Exp. Net | $1,797 | -$897 | $1,036 | $2,797 |
| Pre-Tax Income | -$4,595 | -$6,462 | -$4,822 | -$2,752 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4,585 | -$6,448 | -$4,813 | -$2,740 |
| % Margin | – | -4,960% | – | 19,571.4% |
| EPS | -0.444 | -0.64 | -0.493 | -0.31 |
| % Growth | 30.7% | -29.7% | -59.1% | – |
| EPS Diluted | -0.444 | -0.64 | -0.493 | -0.25 |
| Weighted Avg Shares Out | 10,339 | 10,004 | 9,756 | 8,851 |
| Weighted Avg Shares Out Dil | 10,339 | 10,004 | 9,756 | 10,751 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $6 | $9 | $0 | $17 |
| Depreciation & Amortization | $17 | $16 | $17 | $56 |
| EBITDA | -$4,572 | -$6,437 | -$4,805 | -$2,679 |
| % Margin | – | -4,951.5% | – | 19,135.7% |